Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
Colorcon

Last Updated: August 15, 2022

CLINICAL TRIALS PROFILE FOR OZANIMOD HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Ozanimod Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01628393 ↗ Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients Completed Celgene Phase 2/Phase 3 2012-09-18 This study is a two-part trial consisting of Part A (presented in this record) and Part B (see NCT02047734). The primary objective in Part A of this study was to demonstrate the superior efficacy of ozanimod compared to placebo by showing a reduction in the cumulative number of total gadolinium-enhancing (GdE) lesions from Week 12 to Week 24 in patients with relapsing multiple sclerosis (RMS).
NCT01647516 ↗ Efficacy and Safety Study of Ozanimod in Ulcerative Colitis Completed Celgene Phase 2 2012-12-26 The purpose of this study is to determine whether RPC1063 is effective in the treatment of ulcerative colitis (UC).
NCT02047734 ↗ Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis Completed Celgene Phase 3 2013-12-03 This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record. The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to interferon beta-1a (IFN ╬▓-1a; Avonex┬«) in reducing the rate of clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).
NCT02294058 ↗ Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) Completed Celgene Phase 3 2014-12-03 The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
NCT02531113 ↗ Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease Completed Celgene Phase 2 2015-10-09 The purpose is to determine whether RPC1063 is effective in the treatment of Crohn's disease.
NCT02531126 ↗ Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis Active, not recruiting Celgene Phase 3 2015-12-02 This is an open-label, multicenter, extension trial to evaluate the long-term safety and efficacy of RPC1063 in patients with moderately to severely active ulcerative colitis (UC). The purpose of this extension trial is to evaluate the long-term safety and efficacy of RPC1063 in patients with moderately to severely active ulcerative colitis (UC). Only those patients who have previously participated in a trial of RPC1063, being either RPC01-3101 or completed at least 1 year of the open-label period of RPC01-202 will be eligible
NCT02576717 ↗ A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis Active, not recruiting Celgene Phase 3 2015-10-16 The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ozanimod Hydrochloride

Condition Name

Condition Name for Ozanimod Hydrochloride
Intervention Trials
Healthy Volunteers 6
Crohn Disease 4
Healthy Volunteer 3
Multiple Sclerosis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ozanimod Hydrochloride
Intervention Trials
Sclerosis 6
Multiple Sclerosis 6
Crohn Disease 5
Ulcer 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ozanimod Hydrochloride

Trials by Country

Trials by Country for Ozanimod Hydrochloride
Location Trials
United States 270
Canada 37
Australia 28
Poland 20
Spain 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ozanimod Hydrochloride
Location Trials
Texas 15
California 13
Ohio 12
North Carolina 12
Florida 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ozanimod Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Ozanimod Hydrochloride
Clinical Trial Phase Trials
Phase 4 1
Phase 3 10
Phase 2/Phase 3 2
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ozanimod Hydrochloride
Clinical Trial Phase Trials
Completed 11
Recruiting 9
Active, not recruiting 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ozanimod Hydrochloride

Sponsor Name

Sponsor Name for Ozanimod Hydrochloride
Sponsor Trials
Celgene 22
Bristol-Myers Squibb 4
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ozanimod Hydrochloride
Sponsor Trials
Industry 26
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Boehringer Ingelheim
McKinsey
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.